Eisai Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Region:North America
Product Code:GDPH98590D
September 2018
57
About the Report
Summary
Eisai Inc (Eisai) is a healthcare company, which focuses on the discovery, development and marketing of pharmaceutical products. The company's major products include Aricept for Alzheimer's treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting dring the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company's research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory and immunological reaction. Eisai established partnerships and collaborations with global companies such as Pfizer Inc., Janssen Pharmaceutica Inc., and Elan Pharma International Limited and Elan Pharmaceutical Inc for the development and distribution of drugs. The company is a subsidiary of Eisai Co., Ltd. and is headquartered in New Jersey, the US.
Eisai Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope of the Report
Products
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Eisai Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Eisai Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Eisai Inc, Medical Devices Deals, 2012 to YTD 2018 11
Eisai Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Eisai Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Eisai and Boston University School of Medicine Enter into Research Agreement 14
Morphotek Enters into Research Agreement with Rockefeller University 15
Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 16
Oncology Venture and Eisai Enter into Agreement 17
Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 18
Morphotek Enters into Research Agreement with Fox Chase Cancer Center 19
Novartis Pharma Enters into Agreement with Eisai 20
Morphotek Enters into Agreement with Areva Med 21
Morphotek Enters into Agreement with Mayo Clinic 22
Morphotek Enters into Research Agreement with University of Wisconsin Madison 23
Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 24
Eisai Enters into Research Agreement with Paoli Calmettes Institute 25
Eisai Enters into Agreement with Purdue Pharma 26
Stealth Biologics Enters into Co-Development Agreement with Morphotek 27
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 28
Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 29
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 30
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 32
Licensing Agreements 33
Morphotek Enters into Licensing Agreement with Bliss Biopharma 33
Grupo Biotoscana Enters into Licensing Agreement with Eisai 34
Oncology Venture Enters into Licensing Agreement with Eisai 35
Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 36
Blaze Bioscience Enters into Licensing Agreement with Morphotek 37
NanoCarrier Enters into Licensing Agreement with Eisai 38
Otsuka Pharma Enters Into Licensing Agreement With Eisai 39
Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 40
Asset Transactions 41
Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 41
Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 43
Valeant Pharma Acquires US Rights To Targretin From Eisai 44
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 45
Acquisition 47
Dova Pharma Acquires AkaRx from Eisai 47
Robert Bosch Completes Acquisiton Of Eisai Machinery 49
Eisai Inc-Key Competitors 51
Eisai Inc-Key Employees 52
Eisai Inc-Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Recent Developments 54
Other Significant Developments 54
Dec 05, 2017: Child Neurology Foundation and Eisai Announce New Transitions of Care Resources for Young People Living with Epilepsy 54
Oct 23, 2017: Oncology Venture Updates on Pipeline and Business 55
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.